Sign In
Buy DSS
$0.472
-0.0380 (-7.45%)
At Close: Jun 03, 2026
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepte
DSS, Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing
05:00pm, Friday, 08'th May 2026
ROCHESTER, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced that its annual report (10-K) for the fiscal year ending December 31, 2025, filed on March 31, 2026, includes
DSS, Inc. Letter to Shareholders
04:31pm, Wednesday, 15'th Apr 2026
ROCHESTER, N. Y. , April 15, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today issued the following letter to shareholders from the Interim CEO, Jason Grady, highlighting the Company's ope
DSS, Inc. Announces Closing of $1.0 Million Underwritten Public Offering
09:45am, Thursday, 05'th Feb 2026
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology,
DSS, Inc. Announces Pricing of $1.0 Million Underwritten Public Offering
08:35am, Wednesday, 04'th Feb 2026
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercia
DSS, Inc. Announces Launch of Proposed Public Offering
08:17pm, Tuesday, 03'rd Feb 2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including packaging, wealth management, and biohealth
DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth
08:31am, Thursday, 22'nd May 2025
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating across diverse industries including packaging, real estate, and biomedical innovation, toda
DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth
08:30am, Wednesday, 26'th Feb 2025
ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air pu
DSS, Inc. Issues Letter to Shareholders
08:50am, Monday, 03'rd Feb 2025
NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) a multinational company operating businesses within diversified market sectors that strategically acquires and develops asset
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value
04:26pm, Monday, 16'th Sep 2024
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful
AmericaFirst Funds Trust Announces Changes to Board of Trustees
09:00am, Tuesday, 10'th Sep 2024
NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- AmericaFirst Funds, a subsidiary of DSS, Inc. (NYSE American: DSS), today announced that effective August 9, 2024, David Friedensohn, Monica Himes and Alla
DSS, Inc. Names Jason Grady as Interim Chief Executive Officer
04:08pm, Monday, 26'th Aug 2024
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) has announced the appointment of Jason Grady as its Interim CEO, effective August 23, 2024. Grady, who previously served as C
Yugabyte Embraces ‘No Downtime, No Limits,’ as the Theme of the Upcoming Distributed SQL Summit Asia
09:07pm, Wednesday, 17'th Apr 2024
Experts and Executives from Airwallex, Helpshift, IMDA, Navi, Rakuten, Singtel, Tagbangers, and UL Systems to Present at the Virtual Event SUNNYVALE, Calif.–(BUSINESS WIRE)–Yugabyte, the leading o
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."
08:05am, Tuesday, 30'th Jan 2024
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Lae
DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market
08:15am, Thursday, 04'th Jan 2024
Chairman of the Board Heng Fai Ambrose Chan Adds 672,173 Shares to Increase Investment in Company Chairman of the Board Heng Fai Ambrose Chan Adds 672,173 Shares to Increase Investment in Company
